AIT Therapeutics (AITB) Downgraded by ValuEngine

ValuEngine downgraded shares of AIT Therapeutics (OTCMKTS:AITB) from a buy rating to a hold rating in a report published on Wednesday.

Separately, Zacks Investment Research cut shares of AIT Therapeutics from a hold rating to a sell rating in a report on Tuesday, November 20th.

OTCMKTS AITB opened at $4.94 on Wednesday. AIT Therapeutics has a 52 week low of $2.05 and a 52 week high of $5.50. The company has a market cap of $42.48 million, a price-to-earnings ratio of -1.64 and a beta of -0.32.

AIT Therapeutics (OTCMKTS:AITB) last posted its quarterly earnings results on Wednesday, February 13th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of ($0.21) by $0.32. Equities analysts forecast that AIT Therapeutics will post -0.78 earnings per share for the current fiscal year.

AIT Therapeutics Company Profile

AIT Therapeutics, Inc, a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria.

Featured Story: Buy-Side Analysts

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for AIT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply